Download MendeleyOptimization of Nicotinamides as Potent and Selective IRAK4 Inhibitors with Efficacy in a Murine Model of Psoriasis.
Nair, S., Kumar, S.R., Paidi, V.R., Sistla, R., Kantheti, D., Polimera, S.R., Thangavel, S., Mukherjee, A.J., Das, M., Bhide, R.S., Pitts, W.J., Murugesan, N., Dudhgoankar, S., Nagar, J., Subramani, S., Mazumder, D., Carman, J.A., Holloway, D.A., Li, X., Fereshteh, M.P., Ruepp, S., Palanisamy, K., Mariappan, T.T., Maddi, S., Saxena, A., Elzinga, P., Chimalakonda, A., Ruan, Q., Ghosh, K., Bose, S., Sack, J., Yan, C., Kiefer, S.E., Xie, D., Newitt, J.A., Saravanakumar, S.P., Rampulla, R.A., Barrish, J.C., Carter, P.H., Hynes Jr., J.(2020) ACS Med Chem Lett 11: 1402-1409
- PubMed: 32676146
- DOI: https://doi.org/10.1021/acsmedchemlett.0c00082
- Primary Citation of Related Structures:
6LXY, 6VQL - PubMed Abstract:
IRAK4 is an attractive therapeutic target for the treatment of inflammatory conditions. Structure guided optimization of a nicotinamide series of inhibitors has been expanded to explore the IRAK4 front pocket. This has resulted in the identification of compounds such as 12 with improved potency and selectivity. Additionally 12 demonstrated activity in a pharmacokinetics/pharmacodynamics (PK/PD) model. Further optimization efforts led to the identification of the highly kinome selective 21 , which demonstrated a robust PD effect and efficacy in a TLR7 driven model of murine psoriasis.
Organizational Affiliation:
Biocon Bristol Myers Squibb Research Center, Bangalore 560099, India.
